|
1
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Gallamini
- Research; Innovation and Statistics Department, A Lacassagne Cancer Centre; Nice France
| | - S.M. Ansell
- Department of Medicine; Mayo Clinic; Rochester United States
| | - W.S. Kim
- Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - J. Cheong
- Division of Hematology; Department of Internal Medicine, Yonsei University College of Medicine; Seoul Republic of Korea
| | - I. Flinn
- Department of Oncology; Sarah Cannon Research Institute; Nashville United States
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Kaminski
- Internal Medicine; University of Michigan; Ann Arbor United States
| | - R. Pettengell
- Haematology; St George's Hospital; London United Kingdom
| | - M. Onsum
- Biomarkers; Seattle Genetics, Inc.; Bothell United States
| | - N. Josephson
- Clinical Development; Seattle Genetics, Inc.; Bothell United States
| | - S. Kuroda
- Biostatistics; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan
| | - R. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - H. Miao
- OTAU Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - W.L. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Sureda
- Clinical Hematology; Institut Català d'Oncologia - Hospital Duran i Reynals; Barcelona Spain
| |
Collapse
|
|
2
|
Jagadeesh D, Horwitz S, Bartlett N, Advani R, Jacobsen E, Duvic M, Gautman A, Rao S, Onsum M, Fanale M, Kim Y. RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.149_2631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- D. Jagadeesh
- Hematology and Medical Oncology; Cleveland Clinic; Cleveland United States
| | - S. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - N.L. Bartlett
- Department of Medicine; Oncology Division, Washington University School of Medicine, Siteman Cancer Center; Saint Louis United States
| | - R. Advani
- Medicine-Med/Oncology; Stanford Cancer Institute; Stanford United States
| | - E. Jacobsen
- Division of Hematologic Malignancies; Dana-Farber Cancer Institute; Boston United States
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston United States
| | - A. Gautman
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - S. Rao
- Development; Seattle Genetics, Inc.; Bothell United States
| | - M. Onsum
- Development; Seattle Genetics, Inc.; Bothell United States
| | - M. Fanale
- Development; Seattle Genetics, Inc.; Bothell United States
| | - Y. Kim
- Department of Dermatology; Stanford University School of Medicine; Stanford United States
| |
Collapse
|
|
3
|
Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Tilly H, Belada D, Feldman T, Illés Á, Jacobsen E, Hüttmann A, Zinzani P, O'Connor O, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, Advani R. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.92_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- T. Illidge
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health; University of Manchester, National Institutes of Health and Research Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital National Health Service Foundation Trust; Manchester United Kingdom
| | - S. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Iyer
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, MD Anderson Cancer Center; Houston United States
| | - N. Bartlett
- Department of Medicine; Oncology Division, Washington University School of Medicine, Siteman Cancer Center; Saint Louis United States
| | - W. Kim
- Division of Hematology-Oncology; Department of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel, Université of Rouen Normandie; Rouen France
| | - D. Belada
- 4th Department of Internal Medicine - Haematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Czech Republic
| | - T. Feldman
- Hematology Division; Hackensack University Medical Center; Hackensack United States
| | - Á. Illés
- Department of Hematology; University of Debrecen, Faculty of Medicine; Debrecen Hungary
| | - E. Jacobsen
- Division of Hematologic Malignancies; Dana-Farber Cancer Institute; Boston United States
| | - A. Hüttmann
- Department of Haematology; Universitatsklinikum Essen; Essen Germany
| | - P. Zinzani
- Institute of Hematology; “Seràgnoli” University of Bologna; Bologna France
| | - O.A. O'Connor
- Department of Medicine; Columbia University Medical Center; New York United States
| | - W. Trepicchio
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - H. Miao
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - S. Rao
- Development; Seattle Genetics, Inc.; Bothell United States
| | - M. Onsum
- Development; Seattle Genetics, Inc.; Bothell United States
| | - T. Manley
- Development; Seattle Genetics, Inc.; Bothell United States
| | - R. Advani
- Medicine - Med/Oncology; Stanford Cancer Institute; Stanford United States
| |
Collapse
|
|
4
|
Specht J, Pusztai L, Forero-Torres A, Mita M, Weise A, Krop I, Grosse-Wilde A, Wang Z, Li M, Hengel S, Garfin P, Means G, Onsum M, Modi S. Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.278] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
5
|
Sequist LV, Harb WA, Modiano M, Jackman DM, Wong K, Engelman JA, Nering R, Onsum M, Moyo VM. A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|